Tamsu Tamsulosin
Description: <p><b>Tamsulosin</b> — Selective alpha-1 adrenergic receptor antagonist used primarily for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Tamsulosin preferentially antagonizes alpha-1A and alpha-1D adrenergic receptor subtypes, reducing adrenergically mediated smooth-muscle tone in the prostate, bladder neck, and urinary tract.</p>
<p><b>BPH / LUTS relevance:</b> Strong. Tamsulosin is a standard pharmacologic treatment for BPH-associated lower urinary tract symptoms. It improves urinary flow and reduces symptoms such as hesitancy, weak stream, incomplete emptying, frequency, and nocturia. Its primary effect is relief of the dynamic smooth-muscle component of urinary obstruction rather than reduction of prostate volume.</p>
<p><b>Primary mechanism:</b> Antagonism of alpha-1 adrenergic receptors, particularly ADRA1A and ADRA1D, leading to relaxation of smooth muscle in the prostate and bladder neck and reduced urethral resistance.</p>
<p><b>Typical target/pathway effects:</b> ADRA1A antagonism; ADRA1D antagonism; prostate smooth-muscle tone ↓; bladder-neck smooth-muscle tone ↓; urethral resistance ↓; urinary flow ↑; LUTS severity ↓.</p>
<p><b>Typical clinical dose:</b> 0.4 mg once daily is a common starting dose in BPH treatment. Dose adjustments depend on formulation, response, tolerability, and prescribing guidance.</p>
<p><b>Common adverse effects:</b> Dizziness, orthostatic symptoms, abnormal ejaculation, rhinitis, and headache. Tamsulosin can also contribute to intraoperative floppy iris syndrome during cataract surgery.</p>